Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986504 plus nab-paclitaxel and gemcitabine versus placebo plus nab-paclitaxel and gemcitabine in untreated metastatic MTAP-deleted pancreatic ductal adenocarcinoma
MOH_2025-12-14_015539Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MRTX1719 in pancreatic adenocarcinoma (PDAC), sponsored by Bristol Myers Squibb. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
MRTX1719
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on MOH_2025-12-14_015539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-12-14_015539.